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TO THE EDITOR
Vitiligo is one of the most common
multifactorial, depigmenting disorders
of the skin that results from functional
loss of melanocytes. Various medical
and surgical modalities used to repopu-
late the amelanotic vitiligo lesions have
demonstrated limited outcomes. Pre-
vious studies using autologous non-
cultured epidermal cell suspension
(NCES) transplantation (Mulekar, 2003;
Mulekar, 2005; Gauthier and Benzekri,
2012) and cultured melanocyte
transplantation (CMT) showed variable
results (Chen et al., 2004; Pandya et al.,
2005; Czajkowski et al., 2007; Verma
et al., 2013), as different sets of
individuals were treated either with
NCES or CMT. Therefore, to minimize
inter-individual differences, we have
evaluated the efﬁcacy of CMT versus
NCES in a pilot study on stable vitiligo
cases, where similar lesions of the same
cases were transplanted with either
NCES or CMT.
Two target patches of vitiligo were
grafted with1500 cells/mm2 of NCES on
one site and equal number of CMT on
the other site (Supplementary Materials
and Methods online, Supplementary
Figures S1 and S2 online) after obtaining
informed consent and approval by
Human Ethics Committee of PGIMER,
RMLH, and National Institute of
Immunology following declaration of
Helsinki protocols. After transplantation,
repigmentation was evaluated visually,
by three-dimensional analysis (3-D), using
graph paper and by two-dimensional
(2-D) computerized analysis as descri-
bed in Supplementary Methods online
(Figure 1, Supplementary Figure S1 and
S3 online). Of the 30 vitiligo cases
(Supplementary Tables S1–S3 online)
included in the study, 3 cases were lost
to follow-up, and 27 cases were fol-
lowed up for 3 months for CMT and for
4 months for NCES. Five cases were
followed up for at least 6 months.
Both NCES and CMT resulted in
diffused repigmentation. The visual scor-
ing for repigmentation (Supplementary
Table S4 online) demonstrated that
signiﬁcantly higher number of sites
treated with CMT resulted in excellent
repigmentation (Figure 2d and
Supplementary Figure S4d online) as
compared with NCES-treated sites as
early as eighth week (Po1.23×10−6),
and this trend continued for the 12th
week (Po3.09×10−6). Good repig-
mentation (Supplementary Figure S5d)
was observed in signiﬁcantly higher
number of sites on CMT as compared
with NCES sites as early as fourth week
after transplantation (Po9.32×10−8).
Fair repigmentation (Supplementary
Figure S4b online; Po0.0009) and poor
repigmentation (Figure 2b and
Supplementary Figure S5b online;
Po0.0001) were observed in signiﬁ-
cantly lower number of CMT sites as
compared with the NCES-treated sites.
Three-dimensional analysis (using
graph paper) and 2-D computerized
analysis (using measuring tool of Adobe
Acrobat XI software, Adobe System
Software Ireland Limited, Ireland)
showed similar results (Supplementary
Figure S6 online) and demonstrated
signiﬁcantly higher percent repigmenta-
tion (Po0.0001) in CMT sites (mean±
SEM 80.59±2.8% with 3-D and
81.66± 2.86% with 2-D analysis) com-
pared with NCES sites (28.39±3.5%
with 3-D and 27.73±4.19% with 2-D
analysis, Supplementary Figure S1b
and S1c online). More than 50%
repigmentation was observed in sig-
niﬁcantly higher number of sites
treated with CMT (Supplementary
Table S5 online) at 12th week, com-
pared with NCES-treated sites at 16th
week (Po4.17× 10− 12).
All four segmental vitiligo cases and
25.92% of vitiligo vulgaris cases showed
more than 90% repigmentation with
CMT (Supplementary Figures S3, S7–S9
online). Overall, 66.7% of vitiligo vulgaris
cases showed more than 70% repigmen-
tation with CMT. However, NCES
resulted in less than 40% repigmentation
in all segmental cases and most of the
vitiligo vulgaris cases except three cases
where 57.83, 81.25, and 86.6%
(Supplementary Figure S10a–c online)
repigmentation was achieved. The color
of the repigmented lesions varied
between slightly lighter than the normal
skin and slightly darker than the normal
skin (Supplementary Table S6 online),
which showed subsequent lightening,
matching the normal skin (Supplemen-
tary Figure S11 online). The lesions on the
elbows and dorsum of the foot were
difﬁcult to repigment. Only fair to good
repigmentation could be achieved in
these regions (Supplementary Figures S5,
S12 and S13 online) even with CMT.
All three methods used to evaluate
repigmentation (visual, 3-D and 2-D)
clearly showed signiﬁcantly better
repigmentation with CMT compared
with NCES resulting in signiﬁcantly
better patient satisfaction (Supple-
mentary Table S7 online) with CMT
(Po9.6× 10− 8). Although 3-D analysisAccepted article preview online 7 May 2015; published online 28 May 2015
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takes into account the local curvature of
the lesion and yields the most accurate
measurement (Van Geel et al., 2004), 2-
D digital photograph analysis has its
limitation as it cannot take into account
the 3-D curvature. Because of this
limitation, it may not be possible to
measure all the areas accurately using
2-D images (Van Geel et al., 2004).
However, we were able to do the 2-D
analysis in 25 of the 27 cases studied.
This is the ﬁrst such study, to the best of
our knowledge, where efﬁcacy of CMT
versus NCES has been evaluated on
similar lesions of the same individuals at
3 and 4 months after transplantation,
respectively. The reason for better
repigmentation by CMT is due to the
fact that pure and healthy melanocytes
were being transplanted, which get
populated in the epidermis much faster
compared with melanocytes from NCES
whose proportion is quite low in NCES
(1 melanocyte:10–36 keratinocytes).
Therefore, we were essentially trans-
planting 150 melanocytes/mm2 in
NCES compared with 1,500 melano-
cytes/mm2 in CMT, which resulted in
faster repigmentation. NCES, thus, takes
longer to populate the lesions with
melanocytes and may need more than
one session to achieve better results
(Olsson and Juhlin, 2002). Although we
used PMA-free supplements and do not
expect the cultured melanocytes to
transform, a long-term follow-up is
required to check the potential of the
normal human melanocytes to trans-
form at a later date after transplantation.
Our CMT results are better compared
with the previously reported studies of
Pandya et al. (2005) and Verma et al.
(2013), however, similar to the ones
reported by Hong et al. (2011) and
Chen et al. (2000). The differences from
these previous studies could be
attributed to a small number of
samples, different individuals treated
with the two modalities, and most
importantly the health and purity of
cultured melanocytes as a mixture of
melanocytes and keratinocytes was
used by Pandya et al. (2005) and
Verma et al. (2013). Differences from
the previous studies in terms of NCES
transplantation could be due to the type
of vitiligo (Gauthier and Benzekri,
2012), the use of pre- and post-
operative phototherapies (van Geel
et al., 2001; Zhang et al., 2014) like
psoralen plus UVA or UVB therapy,
longer follow-up, more number of
sessions for NCES transplantation
(Olsson and Juhlin, 2002), and ratio of
the donor to recipient sites, which
varied from 1:3 to 1:5 (Tegta et al.,
2006) and 1:8 to 1:10 (Pandya et al.,
2005; Gauthier and Benzekri, 2012;
Verma et al., 2013) in some of the
earlier studies. Although we used a ratio
of 1:10, it may have been better to use a
donor to recipient site ratio of 1:5 or 1:8
along with post-operative UV therapy to
get better results with NCES. Six-month
follow-up of ﬁve cases, in the present
study, did not show any further
improvement in repigmentation either
with NCES or CMT, suggesting that
there is a need to give another session
of transplantation between 4 and
6 months following initial transplant as
reported earlier (Olsson and Juhlin,
2002). Also, we believe that our CMT
results of 85–98% repigmentation in
about 52% of the sites could be further
enhanced by addition of pre- and post-
operative narrow-band UVB (van Geel
et al., 2001; Zhang et al., 2014).
Major advantage of cellular trans-
plantations is that a small area of donor
skin is needed to cover a large recipient
area with the donor to recipient expan-
sion ratio ranging from 5- to 10-folds.
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Figure 1. 2-D computerized image analysis for calculation of percent area repigmented. (a) Lesional leg before treatment with NCES, (b) lesional area treated
with NCES 16 weeks after treatment, (c) measurement of lesional area and repigmented area using Adobe Acrobat Reader XI, (d) lesional area before treatment
with CMT, (e) lesional area 12 weeks after treatment with CMT, and (f) measurement of lesional and repigmented area using Adobe Acrobat reader XI. The total
lesional area (area in red lines) and the repigmented area (area in black lines) were decided and marked on the image by using measurement tool of Adobe reader
XI software (Ireland). Once the respective areas were drawn, the software displayed the respective measured areas. Percent repigmentation was calculated as
described in Supplementary Materials and Methods online. CMT, cultured melanocyte transplantation; NCES, non-cultured epidermal cell suspension; 2-D, two
dimensional.
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Although several dermatologists have
used NCES grafting, there are very few
reports on CMT due to the lack of
expertise and cost factor. The present
study suggests that CMT may give better
repigmentation as compared with NCES
in stable generalized and segmental
vitiligo as observed at 12th week
follow-up and may be considered as
the treatment of choice for such cases.
However, to be able to use it clinically,
approval from the regulatory bodies in
different countries, like FDA in USA,
would be required.
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EDITOR'S NOTE
In the United States, the Food and Drug Admini-
stration (FDA) forbids the return of human cells to
the person from whom they have been obtained if
they have been manipulated in any way outside
the body unless the procedure has been done
under the auspices of an FDA Investigational New
Drug (IND) approval and in a Good Manufacturing
Conditions (GMC) facility. Thus, unfortunately,
the approach described by Verma et al is
essentially impossible for US investigators and
treating physicians and their patients.
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Figure 2. A vitiligo vulgaris case treated with non-cultured epidermal cell suspension (NCES) and
cultured melanocyte transplant (CMT). (a) Left leg before treatment, (b) left leg 16 weeks after treatment
with NCES showing poor repigmentation, (c) right leg before CMT, and (d) right leg 12 weeks after CMT
showing excellent repigmentation.
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